Diseases & Conditions
Grants & Contracts
News & Events
See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
Are you an NIH staff member? If you have some time and have an interest in helping researchers make discoveries about COVID-19 and influenza, we need you!
We are interested in learning about long-term immunity in people who receive COVID-19 and/or flu vaccines.
The purpose of this study is to evaluate whether IVIG can reduce the severity and duration of flu in people who are hospitalized with the flu.
This study will evaluate how the immune system responds to influenza infection and compare how the infection differs in patients with a weakened immune system versus those with a healthy immune system.
The purpose of this research is to help NIAID researchers understand what happens in kids’ immune systems after receiving a flu vaccine. Researchers are enrolling children who will be receiving the seasonal flu vaccine.
Researchers at the National Institutes of Health (NIH) are studying a new influenza (flu) vaccine that may protect against different flu strains. The study aims to learn more about the safety of this flu vaccine.
The purpose of this observational study is to describe the characteristics and outcomes over a 60-day follow-up period of participants with influenza virus infection (including influenza A subtypes such as H3N2 and 2009 H1N1, or influenza B), or a targeted non-influenza respiratory virus, who are hospitalized with severe illness and/or complication in geographically diverse locations.
If you are healthy, have some time, and have an interest in helping researchers make discoveries about influenza (the flu), we need you for a screening study. The screening is used to determine eligibility for future studies that will help researchers learn more about the development and course of the flu virus.
This NIAID study is investigating why some people who are healthy and have normal immune function become infected with cryptococcosis.
EBV is a herpesvirus that causes mono, technically known as “infectious mononucleosis.” EBV infects roughly 9 out of every 10 people worldwide. This vaccine contains one component of EBV called glycoprotein 350.